Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. / Sørensen, M B; Rosenfalck, A M; Højgaard, L; Ottesen, B.

I: Obesity Research, Bind 9, Nr. 10, 10.2001, s. 622-6.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Sørensen, MB, Rosenfalck, AM, Højgaard, L & Ottesen, B 2001, 'Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy', Obesity Research, bind 9, nr. 10, s. 622-6. https://doi.org/10.1038/oby.2001.81

APA

Sørensen, M. B., Rosenfalck, A. M., Højgaard, L., & Ottesen, B. (2001). Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obesity Research, 9(10), 622-6. https://doi.org/10.1038/oby.2001.81

Vancouver

Sørensen MB, Rosenfalck AM, Højgaard L, Ottesen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obesity Research. 2001 okt.;9(10):622-6. https://doi.org/10.1038/oby.2001.81

Author

Sørensen, M B ; Rosenfalck, A M ; Højgaard, L ; Ottesen, B. / Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. I: Obesity Research. 2001 ; Bind 9, Nr. 10. s. 622-6.

Bibtex

@article{8e4d3fa4610048baa1eda94ffbc869d9,
title = "Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy",
abstract = "OBJECTIVE: Menopause is linked to an increase in fat mass and a decrease in lean mass exceeding age-related changes, possibly related to reduced output of ovarian steroids. In this study we examined the effect of combined postmenopausal hormone replacement therapy (HRT) on the total and regional distribution of fat and lean body mass.RESEARCH METHODS AND PROCEDURES: Sixteen healthy postmenopausal women (age: 55 +/- 3 years) were studied in a placebo-controlled, crossover study and were randomized to 17beta estradiol plus cyclic norethisterone acetate (HRT) or placebo in two 12-week periods separated by a 3-month washout. Total and regional body composition was measured by DXA at baseline and in the 10th treatment week in both periods. Changes were compared by a paired Student's t test.RESULTS: The change in body weight during HRT was equal to the change during placebo (-24.6 g vs. -164 g, p = 0.42), but relative fat mass was significantly reduced (-0.5% vs. +1.24%, p < 0.01). During HRT, compared with during placebo, lean body mass increased (+347 g vs. -996 g, p < 0.01) and total fat mass decreased (-400 g vs. +836 g, p = 0.06). Total bone mineral content increased (+28.9 g vs. -4.4 g, p = 0.04) and abdominal fat decreased (-185 g vs. +253 g, p = 0.04) during HRT compared with placebo.DISCUSSION: HRT is linked to the reversal of both menopause-related obesity and loss of lean mass, without overall change in body weight. The increase in lean body mass during HRT is likely explained by muscle anabolism, which in turn, prevents disease in the elderly.",
keywords = "Absorptiometry, Photon, Adipose Tissue, Body Composition, Bone Density, Cross-Over Studies, Double-Blind Method, Estradiol, Estrogen Replacement Therapy, Female, Humans, Middle Aged, Muscular Atrophy, Norethindrone, Obesity, Postmenopause, Progesterone Congeners, Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",
author = "S{\o}rensen, {M B} and Rosenfalck, {A M} and L H{\o}jgaard and B Ottesen",
year = "2001",
month = oct,
doi = "10.1038/oby.2001.81",
language = "English",
volume = "9",
pages = "622--6",
journal = "Obesity Research",
issn = "1071-7323",
publisher = "The North American Association for the Study of",
number = "10",

}

RIS

TY - JOUR

T1 - Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy

AU - Sørensen, M B

AU - Rosenfalck, A M

AU - Højgaard, L

AU - Ottesen, B

PY - 2001/10

Y1 - 2001/10

N2 - OBJECTIVE: Menopause is linked to an increase in fat mass and a decrease in lean mass exceeding age-related changes, possibly related to reduced output of ovarian steroids. In this study we examined the effect of combined postmenopausal hormone replacement therapy (HRT) on the total and regional distribution of fat and lean body mass.RESEARCH METHODS AND PROCEDURES: Sixteen healthy postmenopausal women (age: 55 +/- 3 years) were studied in a placebo-controlled, crossover study and were randomized to 17beta estradiol plus cyclic norethisterone acetate (HRT) or placebo in two 12-week periods separated by a 3-month washout. Total and regional body composition was measured by DXA at baseline and in the 10th treatment week in both periods. Changes were compared by a paired Student's t test.RESULTS: The change in body weight during HRT was equal to the change during placebo (-24.6 g vs. -164 g, p = 0.42), but relative fat mass was significantly reduced (-0.5% vs. +1.24%, p < 0.01). During HRT, compared with during placebo, lean body mass increased (+347 g vs. -996 g, p < 0.01) and total fat mass decreased (-400 g vs. +836 g, p = 0.06). Total bone mineral content increased (+28.9 g vs. -4.4 g, p = 0.04) and abdominal fat decreased (-185 g vs. +253 g, p = 0.04) during HRT compared with placebo.DISCUSSION: HRT is linked to the reversal of both menopause-related obesity and loss of lean mass, without overall change in body weight. The increase in lean body mass during HRT is likely explained by muscle anabolism, which in turn, prevents disease in the elderly.

AB - OBJECTIVE: Menopause is linked to an increase in fat mass and a decrease in lean mass exceeding age-related changes, possibly related to reduced output of ovarian steroids. In this study we examined the effect of combined postmenopausal hormone replacement therapy (HRT) on the total and regional distribution of fat and lean body mass.RESEARCH METHODS AND PROCEDURES: Sixteen healthy postmenopausal women (age: 55 +/- 3 years) were studied in a placebo-controlled, crossover study and were randomized to 17beta estradiol plus cyclic norethisterone acetate (HRT) or placebo in two 12-week periods separated by a 3-month washout. Total and regional body composition was measured by DXA at baseline and in the 10th treatment week in both periods. Changes were compared by a paired Student's t test.RESULTS: The change in body weight during HRT was equal to the change during placebo (-24.6 g vs. -164 g, p = 0.42), but relative fat mass was significantly reduced (-0.5% vs. +1.24%, p < 0.01). During HRT, compared with during placebo, lean body mass increased (+347 g vs. -996 g, p < 0.01) and total fat mass decreased (-400 g vs. +836 g, p = 0.06). Total bone mineral content increased (+28.9 g vs. -4.4 g, p = 0.04) and abdominal fat decreased (-185 g vs. +253 g, p = 0.04) during HRT compared with placebo.DISCUSSION: HRT is linked to the reversal of both menopause-related obesity and loss of lean mass, without overall change in body weight. The increase in lean body mass during HRT is likely explained by muscle anabolism, which in turn, prevents disease in the elderly.

KW - Absorptiometry, Photon

KW - Adipose Tissue

KW - Body Composition

KW - Bone Density

KW - Cross-Over Studies

KW - Double-Blind Method

KW - Estradiol

KW - Estrogen Replacement Therapy

KW - Female

KW - Humans

KW - Middle Aged

KW - Muscular Atrophy

KW - Norethindrone

KW - Obesity

KW - Postmenopause

KW - Progesterone Congeners

KW - Clinical Trial

KW - Journal Article

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1038/oby.2001.81

DO - 10.1038/oby.2001.81

M3 - Journal article

C2 - 11595778

VL - 9

SP - 622

EP - 626

JO - Obesity Research

JF - Obesity Research

SN - 1071-7323

IS - 10

ER -

ID: 165883161